Volume | 52,241 |
|
|||||
News | - | ||||||
Day High | 21.5599 | Low High |
|||||
Day Low | 20.15 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Jasper Therapeutics Inc | JSPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
21.18 | 20.15 | 21.5599 | 20.40 | 21.18 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,692 | 52,241 | $ 20.97 | $ 1,095,717 | - | 4.00 - 31.01 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:16:27 | 50 | $ 20.50 | USD |
Jasper Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
307M | 15.06M | - | 0 | -64.47M | -4.28 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jasper Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JSPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 23.21 | 24.61 | 20.15 | 21.91 | 69,184 | -2.81 | -12.11% |
1 Month | 30.75 | 31.01 | 20.15 | 25.72 | 77,457 | -10.35 | -33.66% |
3 Months | 12.13 | 31.01 | 11.25 | 22.88 | 117,719 | 8.27 | 68.18% |
6 Months | 7.60 | 31.01 | 4.00 | 8.36 | 360,242 | 12.80 | 168.42% |
1 Year | 11.90 | 31.01 | 4.00 | 10.01 | 346,644 | 8.50 | 71.43% |
3 Years | 140.60 | 188.80 | 3.862 | 56.49 | 829,635 | -120.20 | -85.49% |
5 Years | 140.60 | 188.80 | 3.862 | 56.49 | 829,635 | -120.20 | -85.49% |
Jasper Therapeutics Description
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. |